Guangzhou Boji Medical and Biotechnological Co Ltd (SHE:300404) — Market Cap & Net Worth
Market Cap & Net Worth: Guangzhou Boji Medical and Biotechnological Co Ltd (300404)
Guangzhou Boji Medical and Biotechnological Co Ltd (SHE:300404) has a market capitalization of $756.39 Million (CN¥5.17 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10325 globally and #2748 in its home market, demonstrating a 8.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangzhou Boji Medical and Biotechnological Co Ltd's stock price CN¥13.40 by its total outstanding shares 385748938 (385.75 Million). Also see 300404 total assets for a full breakdown of the balance sheet.
Guangzhou Boji Medical and Biotechnological Co Ltd Market Cap History: 2015 to 2026
Guangzhou Boji Medical and Biotechnological Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.06 Billion to $756.39 Million (-2.21% CAGR). Also see Guangzhou Boji Medical and Biotechnologi cash conversion from operations for how efficiently the company converts equity into cash flow.
Guangzhou Boji Medical and Biotechnological Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangzhou Boji Medical and Biotechnological Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Guangzhou Boji Medical and Biotechnologi stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.61x
Guangzhou Boji Medical and Biotechnological Co Ltd's market cap is 0.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.27x
Guangzhou Boji Medical and Biotechnological Co Ltd's market cap is 17.27 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $768.44 Million | $72.15 Million | $2.09 Million | 10.65x | 368.19x |
| 2017 | $486.06 Million | $130.75 Million | -$24.49 Million | 3.72x | N/A |
| 2018 | $270.30 Million | $172.04 Million | $7.40 Million | 1.57x | 36.53x |
| 2019 | $461.16 Million | $224.06 Million | $6.59 Million | 2.06x | 69.95x |
| 2020 | $445.02 Million | $260.47 Million | $16.99 Million | 1.71x | 26.20x |
| 2021 | $554.97 Million | $324.20 Million | $38.88 Million | 1.71x | 14.27x |
| 2022 | $440.41 Million | $423.68 Million | $27.67 Million | 1.04x | 15.92x |
| 2023 | $504.54 Million | $555.83 Million | $24.34 Million | 0.91x | 20.73x |
| 2024 | $492.78 Million | $742.02 Million | $28.78 Million | 0.66x | 17.12x |
| 2025 | $526.65 Million | $868.64 Million | $30.49 Million | 0.61x | 17.27x |
Competitor Companies of 300404 by Market Capitalization
Companies near Guangzhou Boji Medical and Biotechnological Co Ltd in the global market cap rankings as of September 19, 2026. Review 300404 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guangzhou Boji Medical and Biotechnological Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #455 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Guangzhou Boji Medical and Biotechnological Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangzhou Boji Medical and Biotechnological Co Ltd's market cap moved from $1.06 Billion to $ 756.39 Million, with a yearly change of -2.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥756.39 Million | +43.62% |
| 2025 | CN¥526.65 Million | +6.87% |
| 2024 | CN¥492.78 Million | -2.33% |
| 2023 | CN¥504.54 Million | +14.56% |
| 2022 | CN¥440.41 Million | -20.64% |
| 2021 | CN¥554.97 Million | +24.71% |
| 2020 | CN¥445.02 Million | -3.50% |
| 2019 | CN¥461.16 Million | +70.61% |
| 2018 | CN¥270.30 Million | -44.39% |
| 2017 | CN¥486.06 Million | -36.75% |
| 2016 | CN¥768.44 Million | -27.72% |
| 2015 | CN¥1.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Guangzhou Boji Medical and Biotechnological Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $756.39 Million USD |
| MoneyControl | $756.39 Million USD |
| MarketWatch | $756.39 Million USD |
| marketcap.company | $756.39 Million USD |
| Reuters | $756.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangzhou Boji Medical and Biotechnological Co Ltd
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. The company offers pre-clinical research, clinical research, and other consulting services. It also provides clinical drug production, pilot test scale-up, process verification batch … Read more